The challenge of drug approval in rare cancers
Pexidartinib has emerged as a promising treatment option for patients with advanced tenosynovial giant cell tumors and could demonstrate encouraging long-term control in this patient population. This editorial aims to pick out as a central theme the complex and somehow unfortunate registration statu...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2021
|
| In: |
Cancer
Year: 2021, Volume: 127, Issue: 6, Pages: 837-839 |
| ISSN: | 1097-0142 |
| DOI: | 10.1002/cncr.33314 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/cncr.33314 Verlag, lizenzpflichtig, Volltext: https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.33314 
|
| Author Notes: | Bernd Kasper |
| Summary: | Pexidartinib has emerged as a promising treatment option for patients with advanced tenosynovial giant cell tumors and could demonstrate encouraging long-term control in this patient population. This editorial aims to pick out as a central theme the complex and somehow unfortunate registration status of pexidartinib in Europe in comparison with the United States. |
|---|---|
| Item Description: | First published: 16 November 2020 Gesehen am 16.08.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1097-0142 |
| DOI: | 10.1002/cncr.33314 |